<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03795792</url>
  </required_header>
  <id_info>
    <org_study_id>R-2017-785-132</org_study_id>
    <nct_id>NCT03795792</nct_id>
  </id_info>
  <brief_title>Oral Curcumin Administration to Remit Metabolic Syndrome</brief_title>
  <official_title>Efficacy of Oral Curcumin Administration on Metabolic Syndrome Remission.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic syndrome consists of a set of risk factors that increases the probability to&#xD;
      develop heart diseases and type 2 diabetes, two of the principal chronic diseases that affect&#xD;
      Mexican population. The curcumin is a compound that is extracted from the root of a plant&#xD;
      called Cúrcuma longa. There exists information that curcumin helps to diminish weight and the&#xD;
      levels of blood glucose and blood fats. The hypothesis of this study is: that curcumin&#xD;
      administration combined with diet and exercise remits the metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The aim of this study is to determinate the efficacy of oral administration of&#xD;
      curcumin in the remission of metabolic syndrome.&#xD;
&#xD;
      Design: clinical trial, randomized, double blind, placebo controlled.&#xD;
&#xD;
      Study population: Men and women from 20 to 55 years old with metabolic syndrome according to&#xD;
      the ATP III criteria, will be included.&#xD;
&#xD;
      Study groups: intervention and control group.&#xD;
&#xD;
      Sample size: It was calculated using a statistical power of 80%, an alpha value of 0.05. A&#xD;
      50% of the difference in the mean of remission of metabolic syndrome between control group&#xD;
      and intervention groups was considered. The estimated sample size was 220 subjects for each&#xD;
      group.&#xD;
&#xD;
      Process: All eligible participants according to inclusion and exclusion criteria, will be&#xD;
      randomized to one of the study groups.&#xD;
&#xD;
      The intervention group will receive a total dose of curcumin 1.2 g / black pepper 10 mg a&#xD;
      day; and control group will receive a total dose of hydrolyzed collagen 1.2 g / black pepper&#xD;
      10 mg a day; plus dietary and exercise recommendations for both groups during three months.&#xD;
&#xD;
      The blood concentrations of glucose, triglycerides, and HDL cholesterol will be measured, as&#xD;
      well as the abdominal perimeter and blood pressure, at baseline conditions, at one month and&#xD;
      three months after treatment.&#xD;
&#xD;
      Statistical analysis: Numerical values will be expressed as mean ± standard deviation;&#xD;
      categorical variables will be expressed as proportions. Differences between the groups were&#xD;
      estimated by unpaired Student t test for numerical variables (Mann-Whitney U test for skewed&#xD;
      data) or Chi-square and Fisher´s exact test for categorical variables. Intragroup differences&#xD;
      were estimated by paired Student t-test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2018</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study groups:&#xD;
Intervention group: curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.&#xD;
Control group: hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Neither the patient nor the treating doctor will know the study group the participant was randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of metabolic syndrome.</measure>
    <time_frame>Three months.</time_frame>
    <description>Presence of two or less metabolic syndrome criteria, according to the ATP III criteria.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrollased collagen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Will be provided in capsules</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Turmeric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hydrolyzed collagen</intervention_name>
    <description>Will be provided in capsules.</description>
    <arm_group_label>Hydrollased collagen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women and men.&#xD;
&#xD;
          -  20 to 55 years old.&#xD;
&#xD;
          -  Diagnosis of metabolic syndrome according to the ATP III criteria.&#xD;
&#xD;
          -  Informed consent of the participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes or hypoglycaemic therapy.&#xD;
&#xD;
          -  High blood pressure o anti-hypertensive treatments.&#xD;
&#xD;
          -  Hypertriglyceridemia (&gt;400 g/dL) or lipid lowering treatment.&#xD;
&#xD;
          -  Neoplasia disease.&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Syndrome of polycystic ovary.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Smoking.&#xD;
&#xD;
          -  Anti-inflammatory medicines in the last two months.&#xD;
&#xD;
          -  Food supplements in the last two months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Guerrero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Simental, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerardo Martínez, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Gamboa, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biomedical Research Unit. IMSS. Durango</name>
      <address>
        <city>Durango</city>
        <state>Dgo</state>
        <zip>34067</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Azhar Y, Parmar A, Miller CN, Samuels JS, Rayalam S. Phytochemicals as novel agents for the induction of browning in white adipose tissue. Nutr Metab (Lond). 2016 Dec 3;13:89. doi: 10.1186/s12986-016-0150-6. eCollection 2016.</citation>
    <PMID>27980598</PMID>
  </reference>
  <reference>
    <citation>Cabrera-Rode E, Stusser B, Calix W, Orlandi N, Rodriguez J, Cubas-Duenas I, Echevarria R, Alvarez A. [Diagnostic concordance between seven definitions of metabolic syndrome in overweight and obese adults]. Rev Peru Med Exp Salud Publica. 2017 Jan-Mar;34(1):19-27. doi: 10.17843/rpmesp.2017.341.2763. Spanish.</citation>
    <PMID>28538842</PMID>
  </reference>
  <reference>
    <citation>Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4195-202.</citation>
    <PMID>26592847</PMID>
  </reference>
  <reference>
    <citation>Jimenez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance-Molecular targets and clinical evidences. Biofactors. 2016 Nov 12;42(6):561-580. doi: 10.1002/biof.1302. Epub 2016 Jun 21.</citation>
    <PMID>27325504</PMID>
  </reference>
  <reference>
    <citation>Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract. 2010 Jun;4(3):191-5. doi: 10.4162/nrp.2010.4.3.191. Epub 2010 Jun 28.</citation>
    <PMID>20607063</PMID>
  </reference>
  <reference>
    <citation>Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. Biofactors. 2013 Jan-Feb;39(1):14-20. doi: 10.1002/biof.1042. Epub 2012 Sep 20.</citation>
    <PMID>22996406</PMID>
  </reference>
  <reference>
    <citation>Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res. 2013 Mar;27(3):374-9. doi: 10.1002/ptr.4715. Epub 2012 May 21.</citation>
    <PMID>22610853</PMID>
  </reference>
  <reference>
    <citation>Na LX, Yan BL, Jiang S, Cui HL, Li Y, Sun CH. Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes. Biomed Environ Sci. 2014 Nov;27(11):902-6. doi: 10.3967/bes2014.127.</citation>
    <PMID>25374024</PMID>
  </reference>
  <reference>
    <citation>Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013 Sep;57(9):1569-77. doi: 10.1002/mnfr.201200131. Epub 2012 Aug 29.</citation>
    <PMID>22930403</PMID>
  </reference>
  <reference>
    <citation>Neyrinck AM, Alligier M, Memvanga PB, Nevraumont E, Larondelle Y, Preat V, Cani PD, Delzenne NM. Curcuma longa extract associated with white pepper lessens high fat diet-induced inflammation in subcutaneous adipose tissue. PLoS One. 2013 Nov 19;8(11):e81252. doi: 10.1371/journal.pone.0081252. eCollection 2013.</citation>
    <PMID>24260564</PMID>
  </reference>
  <reference>
    <citation>Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, Kazemi Oskuee R. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577.</citation>
    <PMID>27761427</PMID>
  </reference>
  <reference>
    <citation>Kowluru RA, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond). 2007 Apr 16;4:8. doi: 10.1186/1743-7075-4-8.</citation>
    <PMID>17437639</PMID>
  </reference>
  <reference>
    <citation>Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215-225. doi: 10.1177/1753944717711379. Epub 2017 Jun 22.</citation>
    <PMID>28639538</PMID>
  </reference>
  <reference>
    <citation>Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG, Jin T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012;7(1):e28784. doi: 10.1371/journal.pone.0028784. Epub 2012 Jan 9.</citation>
    <PMID>22253696</PMID>
  </reference>
  <reference>
    <citation>Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol Med. 2012 Mar;18(3):138-44. doi: 10.1016/j.molmed.2012.01.004. Epub 2012 Mar 1.</citation>
    <PMID>22386732</PMID>
  </reference>
  <reference>
    <citation>Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res. 2011 Dec;55(12):1829-40. doi: 10.1002/mnfr.201100440. Epub 2011 Nov 7.</citation>
    <PMID>22058071</PMID>
  </reference>
  <reference>
    <citation>Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014 Dec;28(12):1770-7. doi: 10.1002/ptr.5197. Epub 2014 Aug 6.</citation>
    <PMID>25131839</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Guerrero Romero MD</investigator_full_name>
    <investigator_title>Head of the research unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03795792
org study id: R-2017-785-132
nct id: NCT03795792
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The metabolic syndrome consists of a set of risk factors that increases the probability to
      develop heart diseases and type 2 diabetes, two of the principal chronic diseases that affect
      Mexican population. The curcumin is a compound that is extracted from the root of a plant
      called Cúrcuma longa. There exists information that curcumin helps to diminish weight and the
      levels of blood glucose and blood fats. The hypothesis of this study is: that curcumin
      administration combined with diet and exercise remits the metabolic syndrome.
Objective: The aim of this study is to determinate the efficacy of oral administration of
      curcumin in the remission of metabolic syndrome.

      Design: clinical trial, randomized, double blind, placebo controlled.

      Study population: Men and women from 20 to 55 years old with metabolic syndrome according to
      the ATP III criteria, will be included.

      Study groups: intervention and control group.

      Sample size: It was calculated using a statistical power of 80%, an alpha value of 0.05. A
      50% of the difference in the mean of remission of metabolic syndrome between control group
      and intervention groups was considered. The estimated sample size was 220 subjects for each
      group.

      Process: All eligible participants according to inclusion and exclusion criteria, will be
      randomized to one of the study groups.

      The intervention group will receive a total dose of curcumin 1.2 g / black pepper 10 mg a
      day; and control group will receive a total dose of hydrolyzed collagen 1.2 g / black pepper
      10 mg a day; plus dietary and exercise recommendations for both groups during three months.

      The blood concentrations of glucose, triglycerides, and HDL cholesterol will be measured, as
      well as the abdominal perimeter and blood pressure, at baseline conditions, at one month and
      three months after treatment.

      Statistical analysis: Numerical values will be expressed as mean ± standard deviation;
      categorical variables will be expressed as proportions. Differences between the groups were
      estimated by unpaired Student t test for numerical variables (Mann-Whitney U test for skewed
      data) or Chi-square and Fisher´s exact test for categorical variables. Intragroup differences
      were estimated by paired Student t-test.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Study groups:
Intervention group: curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
Control group: hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
primary purpose: Treatment
masking: Double (Participant, Care Provider)
masking description: Neither the patient nor the treating doctor will know the study group the participant was randomized.
measure: Remission of metabolic syndrome.
time frame: Three months.
description: Presence of two or less metabolic syndrome criteria, according to the ATP III criteria.
arm group label: Curcumin
arm group type: Experimental
description: Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
arm group label: Hydrollased collagen
arm group type: Placebo Comparator
description: Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
intervention type: Dietary Supplement
intervention name: Curcumin
description: Will be provided in capsules
arm group label: Curcumin
other name: Turmeric
intervention type: Dietary Supplement
intervention name: Hydrolyzed collagen
description: Will be provided in capsules.
arm group label: Hydrollased collagen
criteria: 
gender: All
minimum age: 20 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Fernando Guerrero, PhD
role: Principal Investigator
affiliation: Instituto Mexicano del Seguro Social
last name: Luis Simental, PhD
role: Study Chair
affiliation: Instituto Mexicano del Seguro Social
last name: Gerardo Martínez, PhD
role: Study Chair
affiliation: Instituto Mexicano del Seguro Social
last name: Claudia Gamboa, PhD
role: Study Chair
affiliation: Instituto Mexicano del Seguro Social
facility: 
country: Mexico
citation: Azhar Y, Parmar A, Miller CN, Samuels JS, Rayalam S. Phytochemicals as novel agents for the induction of browning in white adipose tissue. Nutr Metab (Lond). 2016 Dec 3;13:89. doi: 10.1186/s12986-016-0150-6. eCollection 2016.
PMID: 27980598
citation: Cabrera-Rode E, Stusser B, Calix W, Orlandi N, Rodriguez J, Cubas-Duenas I, Echevarria R, Alvarez A. [Diagnostic concordance between seven definitions of metabolic syndrome in overweight and obese adults]. Rev Peru Med Exp Salud Publica. 2017 Jan-Mar;34(1):19-27. doi: 10.17843/rpmesp.2017.341.2763. Spanish.
PMID: 28538842
citation: Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4195-202.
PMID: 26592847
citation: Jimenez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance-Molecular targets and clinical evidences. Biofactors. 2016 Nov 12;42(6):561-580. doi: 10.1002/biof.1302. Epub 2016 Jun 21.
PMID: 27325504
citation: Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract. 2010 Jun;4(3):191-5. doi: 10.4162/nrp.2010.4.3.191. Epub 2010 Jun 28.
PMID: 20607063
citation: Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. Biofactors. 2013 Jan-Feb;39(1):14-20. doi: 10.1002/biof.1042. Epub 2012 Sep 20.
PMID: 22996406
citation: Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res. 2013 Mar;27(3):374-9. doi: 10.1002/ptr.4715. Epub 2012 May 21.
PMID: 22610853
citation: Na LX, Yan BL, Jiang S, Cui HL, Li Y, Sun CH. Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes. Biomed Environ Sci. 2014 Nov;27(11):902-6. doi: 10.3967/bes2014.127.
PMID: 25374024
citation: Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013 Sep;57(9):1569-77. doi: 10.1002/mnfr.201200131. Epub 2012 Aug 29.
PMID: 22930403
citation: Neyrinck AM, Alligier M, Memvanga PB, Nevraumont E, Larondelle Y, Preat V, Cani PD, Delzenne NM. Curcuma longa extract associated with white pepper lessens high fat diet-induced inflammation in subcutaneous adipose tissue. PLoS One. 2013 Nov 19;8(11):e81252. doi: 10.1371/journal.pone.0081252. eCollection 2013.
PMID: 24260564
citation: Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, Kazemi Oskuee R. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577.
PMID: 27761427
citation: Kowluru RA, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond). 2007 Apr 16;4:8. doi: 10.1186/1743-7075-4-8.
PMID: 17437639
citation: Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215-225. doi: 10.1177/1753944717711379. Epub 2017 Jun 22.
PMID: 28639538
citation: Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG, Jin T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012;7(1):e28784. doi: 10.1371/journal.pone.0028784. Epub 2012 Jan 9.
PMID: 22253696
citation: Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol Med. 2012 Mar;18(3):138-44. doi: 10.1016/j.molmed.2012.01.004. Epub 2012 Mar 1.
PMID: 22386732
citation: Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res. 2011 Dec;55(12):1829-40. doi: 10.1002/mnfr.201100440. Epub 2011 Nov 7.
PMID: 22058071
citation: Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014 Dec;28(12):1770-7. doi: 10.1002/ptr.5197. Epub 2014 Aug 6.
PMID: 25131839
responsible party type: Principal Investigator
investigator affiliation: Coordinación de Investigación en Salud, Mexico
investigator full name: Fernando Guerrero Romero MD
investigator title: Head of the research unit
mesh term: Metabolic Syndrome
mesh term: Syndrome
mesh term: Curcumin
sharing ipd: No